Holen Sie sich die Stockscreener-App
1.505
0.33%
0.005
Schlusskurs vom Vortag:
$1.50
Offen:
$1.51
24-Stunden-Volumen:
383.00K
Relative Volume:
0.43
Marktkapitalisierung:
$160.54M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-4.4265
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
-2.90%
1M Leistung:
+2.38%
6M Leistung:
-30.65%
1J Leistung:
-65.64%
1-Tages-Spanne:
$1.475
$1.54
1-Wochen-Bereich:
$1.475
$1.59
52-Wochen-Spanne:
$1.26
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.505 | 160.01M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
127.08 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.65 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.92 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.81 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.78 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
Will MaxCyte Inc. stock deliver strong dividend growth2026 world cup usa national team group stage defensive leaders pressing system tactical prediction guide - ulpravda.ru
MaxCyte eyes growth in cell engineering for 2026 - Traders Union
Will MaxCyte Inc. stock attract more institutional investorsEarnings Forecast Updates & Build Wealth With Strategy - bollywoodhelpline.com
MXCT’s price-to-cash ratio: How it affects the stock’s valuation. - uspostnews.com
MaxCyte advances GMP process with KSQ partnership - Traders Union
Activity Recap: Why GIGGU stock appeals to dividend seekersTrade Entry Report & Smart Allocation Stock Reports - moha.gov.vn
Will MaxCyte Inc. stock benefit from sector rotationShare Buyback & Capital Efficient Trade Techniques - Улправда
Why retail investors pile into MaxCyte Inc. stock2025 Price Targets & Fast Entry Momentum Trade Alerts - Улправда
How sustainable is MaxCyte Inc. stock dividend payoutLong Setup & Comprehensive Market Scan Insights - DonanımHaber
Is MaxCyte Inc. stock a bargain at current levels2025 Major Catalysts & Free Long-Term Investment Growth Plans - Улправда
Stock Recap: How buybacks impact MaxCyte Inc. stock valueJuly 2025 Summary & Verified Technical Trade Signals - DonanımHaber
MaxCyte, Inc.(NasdaqGS: MXCT) dropped from NASDAQ Biotechnology Index - marketscreener.com
MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
William Blair Downgrades MaxCyte (MXCT) - MSN
Prepare Yourself for Liftoff: MaxCyte Inc (MXCT) - setenews.com
Healthy Upside Potential: MaxCyte Inc (MXCT) - setenews.com
Mirabella Financial Services LLP Has $14.39 Million Stock Position in MaxCyte, Inc. $MXCT - MarketBeat
How MaxCyte Inc. (MYE0) stock compares with market leadersWeekly Stock Report & Smart Swing Trading Techniques - Newser
Is MaxCyte Inc. (MYE0) stock attractive post correction2025 Top Gainers & Daily Price Action Insights - Newser
Can MaxCyte Inc. (MYE0) stock stage a strong rebound this quarterJuly 2025 Sector Moves & Short-Term Swing Trade Alerts - Newser
Is MaxCyte Inc. stock attractive for ETFsTrade Risk Summary & Consistent Return Strategy Ideas - Newser
Why analysts recommend MaxCyte Inc. (MYE0) stockJuly 2025 Trends & Weekly Setup with ROI Potential - Newser
Is MaxCyte Inc. (MYE0) stock dividend growth reliableAnalyst Upgrade & Stepwise Trade Execution Plans - Newser
MaxCyte drives CAR T manufacturing optimization using ExPERT system - Traders Union
Dividend Watch: Why Clearway Energy Inc. (NY4B) stock is upgraded to buyJuly 2025 Volume & Verified Technical Signals - BỘ NỘI VỤ
MaxCyte (MXCT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO - Morningstar
The time has not yet come to remove your chips from the table: MaxCyte Inc (MXCT) - setenews.com
MaxCyte aims to optimize CAR T manufacturing with ExPERT system - Traders Union
MaxCyte (NASDAQ:MXCT) Stock Rating Upgraded by Wall Street Zen - Defense World
MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of "Hold" from Analysts - MarketBeat
MaxCyte: Building the Future of Cell and Gene Therapy Innovation - MSN
MXCT SEC FilingsMaxcyte 10-K, 10-Q, 8-K Forms - Stock Titan
What drives MaxCyte Inc MYE0 stock priceRSI Overbought/Oversold & Daily Tips From Top Market Analysts - earlytimes.in
How MaxCyte Inc. (MYE0) stock reacts to fiscal policiesJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Can MaxCyte Inc. (MYE0) stock reach $200 price target2025 Major Catalysts & Weekly High Return Opportunities - newser.com
MaxCyte explores electroporation's role in cell therapy innovation - Traders Union
How MaxCyte Inc. (MYE0) stock behaves under inflation pressureEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
What Wall Street predicts for MaxCyte Inc. stock priceQuarterly Earnings Report & Risk Managed Investment Entry Signals - newser.com
MaxCyte drives cell engineering focus at Advanced Therapies USA - Traders Union
MaxCyte Announces Major Workforce Reduction Plan - MSN
Is MaxCyte Inc. stock a buy in volatile marketsJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - newser.com
MaxCyte at Stephens Annual Investment Conference: Strategic Restructuring Amid Market Challenges By Investing.com - Investing.com Canada
Will MaxCyte Inc. stock split again soonTrade Risk Report & Daily Profit Maximizing Tips - newser.com
A Look at MaxCyte Inc (MXCT) Shares in the Recent Past Indicates Growth - Setenews
Is MaxCyte Inc. (MYE0) stock nearing a technical breakoutPortfolio Gains Summary & Community Consensus Picks - newser.com
MXCT: SecureDx integration and new product launches position for growth as industry rationalizes - TradingView — Track All Markets
What dividend safety rating applies to MaxCyte Inc. (MYE0) stockIPO Watch & Safe Capital Growth Trade Ideas - newser.com
How MaxCyte Inc. (MYE0) stock trades under stagflation2025 Performance Recap & Entry Point Strategy Guides - newser.com
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
1.20%
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):